Showing 3651-3660 of 6035 results for "".
- More Adults with Vision Loss Seeking Help Staying Connected During Pandemichttps://modernod.com/news/more-adults-with-vision-loss-seeking-help-staying-connected-during-pandemic/2478772/Since the onset of COVID-19 those with visual impairments have faced disproportionate vulnerabilities from living in extended isolation. Newly released data has shown that clinical depression within the visually impaired community is being reported at nearly three times the level than the general
- Biden Picks Former FDA Commissioner David Kessler to Lead Operation Warp Speedhttps://modernod.com/news/biden-picks-former-fda-commissioner-david-kessler-to-lead-operation-warp-speed/2478768/US President-elect Joe Biden announced a number of appointments to the incoming team handling the response to the COVID-19 pandemic, including naming David Kessler as chief science officer. Mr. Kessler, who served as FDA commissioner between 1990 and 1997, will reportedly share oversight of Opera
- Sources: FDA Veteran Woodcock Being Considered to Lead Agency Under Bidenhttps://modernod.com/news/sources-fda-veteran-woodcock-being-considered-to-lead-agency-under-biden/2478764/Janet Woodcock, a 30-year veteran of the Food and Drug Administration, is being considered by President-elect Joe Biden to serve as commissioner of the agency, Bloomberg reported,
- Glaukos’ iDose TR Demonstrates Sustained IOP Reduction and Favorable Safety Profile Over 24 Months in Phase 2b Studyhttps://modernod.com/news/glaukos-idose-tr-demonstrates-sustained-iop-reduction-and-favorable-safety-profile-over-24-months-in-phase-2b-study/2478753/Glaukos announced that its iDose TR sustained-release travoprost implant continued to provide sustained substantial reductions in IOP in a 24-month interim analysis of the ongoing 36-month phase 2b clinical trial conducted under a U.S. investigational new drug (IND) protocol. Administered
- Notal Vision Launches First US Home OCT Longitudinal Study with Patient Self-Operated Devicehttps://modernod.com/news/notal-vision-launches-first-us-home-oct-longitudinal-study-with-patient-self-operated-device/2478748/Notal Vision announced that it has initiated the first US-based study using its investigational home-based optical coherence tomography (OCT) platform. The study will evaluate the ability of subjects with wet age-rela
- Turn Biotechnologies Licenses Technology that Aims to Unwind the Effects of Aging at a Cellular Levelhttps://modernod.com/news/turn-biotechnologies-licenses-technology-that-aims-to-unwind-the-effects-of-aging-at-a-cellular-level/2478747/Turn Biotechnologies announced that it has acquired the global rights for new technology that aims to reprogram cells to undo many of the effects of aging. The company licensed its epigenetic reprogramming of age (ERA) technology from Stanford University, where
- Aviceda Therapeutics Announces Formation of Executive Teamhttps://modernod.com/news/aviceda-therapeutics-announces-formation-of-executive-team/2478745/Aviceda Therapeutics has announced the composition of the Executive Team that will guide the company through ongoing development of first-in-class therapeutics and continued growth opportunities as a business entity. Aviceda’s lead ophthalmic optimized nanoparticle, as an intravitreal form
- EyeSouth Partners Expands Network to Include 28 Doctors in Ohio and Kentucky Through Affiliation with Midwest Eye Centerhttps://modernod.com/news/eyesouth-partners-expands-network-to-include-28-doctors-in-ohio-and-kentucky-through-affiliation-with-midwest-eye-center/2478742/EyeSouth Partners has announced that it has completed an affiliation with Midwest Eye Center (MWEC), representing EyeSouth’s first in the states of Ohio and Kentucky. Terms of the deal were not disclosed. Midwest Eye Center is led by Drs. Mark Cepela, Jean Noll, Faiz Khaja, Saif Jaw
- AsclepiX Therapeutics Doses First Patient in Phase 1/2a Trial of AXT107 Intravitreal Self-Forming Gel Depot Peptide for DMEhttps://modernod.com/news/asclepix-therapeutics-doses-first-patient-in-phase-1-2a-trial-of-axt107-intravitreal-self-forming-gel-depot-peptide-for-dme/2478717/AsclepiX Therapeutics announced that the first patient has been dosed in the phase 1/2a CONGO clinical trial to evaluate the safety and bioactivity of AXT107 in patients with diabetic macular edema (DME). “Dosing the first patient with AXT107 shortly after the acceptance of its IND is a si
- Three Optometry Practices in Southwest Florida Partner With Private Equity Firm US Eyehttps://modernod.com/news/three-optometry-practices-in-southwest-florida-partner-with-private-equity-firm-us-eye/2478699/Three optometry practices in Southwest Florida—Bayside Eye Center, Fort Myers Eye Center and Valentine Eye Care—have partnered with US Eye and Center For Sight. Financial terms of the deal were not disclosed. Center For Sight is a founding member practice of US Eye, a physician-led,